Recruiting

Testing a new cell therapy for rare T and NK cell cancers

Plain-English translation of NCT07382817 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called for people with rare cancers of T and NK cells (types of immune cells) that have returned after previous treatment or no longer respond to standard therapy. is a type of cell therapy — doctors take your own immune cells, reprogram them in the laboratory to better fight your cancer, and then put them back into your body as a single infusion. This early-stage study aims to find the safest and most effective dose of this medication.

T and NK cell cancers are rare and often difficult to treat, especially once they come back or stop responding to standard chemotherapy and other available options. This trial exists to see whether this medication — which uses your own immune cells as a personalized weapon against cancer — can help patients who have limited choices left.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with a T or NK cell cancer that has come back after treatment or stopped responding to treatment
you have received at least one previous line of cancer therapy or cannot tolerate standard treatments
your cancer cells test positive for a marker called CD94 (at least 50% of your tumor cells)
you have adequate organ function, including normal kidney, liver, heart, and lung function, and acceptable blood cell counts
you have recovered from side effects of any previous cancer treatment and are in good enough health to receive this therapy (ECOG performance status 0-1)

You likely don't qualify if…

you have aggressive NK cell leukemia or certain indolent (slow-growing) T and NK cell cancers
your cancer cells are circulating in high numbers in your bloodstream
you have active cancer in your brain, spine, or cerebrospinal fluid
you are pregnant or unable to use contraception if of childbearing potential
you have severe organ dysfunction or low blood cell counts that put you at high risk

What participation looks like

If you enroll, your own T cells will be collected in an outpatient procedure called leukapheresis. These cells are then sent to a laboratory where they are modified and grown. Once ready, you will return to the hospital or clinic to receive your modified cells back as a single infusion over less than 30 minutes. You may be hospitalized afterward for safety monitoring. The trial will track your response to the treatment, how long it lasts, and any side effects over time.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Trial locations(1 site)

United States

The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Testing a new cell therapy for rare T and NK cell cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)

Contact the research team directly

Interested in joining?